Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Myelodysplastic Syndromes – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders, which result in cytopenia and an increased risk of progression to acute myeloid leukemia (AML)…
Acute Myeloid Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)
Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new…
Acute Lymphoblastic Leukemia – Current Treatment – Treatment Sequencing – Acute Lymphoblastic Leukemia (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
Multiple Myeloma – Unmet Need – Unmet Need – Third- and Fourth-Line Multiple Myeloma (US/EU)
The treatment of multiple myeloma is complex, often involving combinations of CD38-blocking monoclonal antibodies (MAbs), immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), chemotherapy,…
Non-Hodgkin’s Lymphoma – Current Treatment – Current Treatment: Physician Insights – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)
Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) encompass a heterogeneous group of hematological malignancies broadly classified into indolent and aggressive subtypes…
Non-Hodgkin’s Lymphoma – Current Treatment – Treatment Sequencing – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Myelofibrosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Myelofibrosis is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The JAK…
Non-Hodgkin’s Lymphoma – Geographic Focus: China – China In-Depth – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
The launch of several novel therapies, as well as multiple label expansions of existing drugs, will fuel significant growth of the NHL therapy market in China over the next 10 years. Rituximab (…
